Citations

Clear

13 citation(s) found for "Brinkman, Hannah".

1637: CLINICAL OUTCOMES OF ROUTINE ANTITHROMBIN SUPPLEMENTATION DURING EXTRACORPOREAL MEMBRANE OXYGENATION
Elliott, Abigail, Brinkman, Hannah, Seelhammer, Troy, Klompas, Allan, Gerberi, Danielle, Cole, Kristin, Wittwer, Erica, Wieruszewski, Patrick, Brinkman, Hannah M. , Seelhammer, Troy G. , Klompas, Allan M. , Wittwer, Erica D. , Wieruszewski, Patrick M.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001188544.50398.10 Get It

1460: ACTIVATED FACTOR VII USE FOR REFRACTORY HEMORRHAGE ON ECMO
Martin, Nate, Brinkman, Hannah, Esmaeilzadeh, Sarvie , Wittwer, Erica, Seelhammer, Troy, Wieruszewski, Patrick, Brinkman, Hannah M. , Wittwer, Erica D. , Seelhammer, Troy G. , Wieruszewski, Patrick M.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001187836.29703.b5 Get It

Antithrombin Supplementation in Extracorporeal Membrane Oxygenation: A Systematic Review With Meta‐Analysis
Elliott, Abigail G., Brinkman, Hannah M. , Seelhammer, Troy G. , Gerberi, Dana , Cole, Kristin C., Wittwer, Erica D. , Wieruszewski, Patrick M. , Klompas, Allan M. , Wieruszewski, Patrick M , Elliott, Abigail G., Cole, Kristin C.

Mayo Clinic

Artificial Organs | November 20, 2025 | Volume: 50 | Issue: 6 | Pages: 797-808

10.1111/aor.70057 | PMID 41263426 Get It

ABSTRACT Background The Extracorporeal Life Support Organization recommends daily antithrombin monitoring and supplementation to achieve > 50%–80% activity during extracorporeal membrane oxygenation (ECMO). Evidence supporting this practice is uncertain, and whether it confers clinical benefit or harm is unclear. Methods This was a systematic review with meta‐analysis to evaluate the safety and efficacy of antithrombin supplementation during ECMO. We systematically searched databases and registers for studies comparing patients on ECMO who received antithrombin supplementation to those who did not. Random effects meta‐analysis was performed. Risk of bias was independently assessed by two investigators. A priori subgroup and sensitivity analyses were performed to explore reasons for heterogeneity. Results A total of 11 studies were identified. In the pooled meta‐analysis, antithrombin supplementation resulted in no difference in bleeding events (OR 1.38, 95% CI, 0.88–2.17, p = 0.16), thrombotic events (OR 1.57, 95% CI, 0.84–2.90, p = 0.15), or mortality (OR 1.21, 95% CI, 0.81–1.81, p = 0.35) when compared to those who did not receive antithrombin. Subgroup analysis revealed no difference in bleeding events or mortality in pediatric or adult patients; however, pediatric patients that received antithrombin were more likely to experience a thrombotic event (OR 1.70, 95% CI, 1.51–1.91). Sensitivity analysis in only low risk of bias studies confirmed these findings. Conclusions Antithrombin supplementation was not associated with differences in mortality or hemostatic outcomes during ECMO support and may be associated with harm in pediatric patients on ECMO.
297: Itraconazole Exposure in Patients Receiving Extracorporeal Membrane Oxygenation
Martin, Nate, Brinkman, Hannah, Seelhammer, Troy, Stevens, Ryan, Kim, MJ, Shah, Adi, Wieruszewski, Patrick, Martin, Nate, Brinkman, Hannah, Seelhammer, Troy, Stevens, Ryan, Kim, MJ, Shah, Adi, Wieruszewski, Patrick

Mayo Clinic

ASAIO Journal | September 26, 2025 | Volume: 71 | Issue: Supplement 4 | Pages: 35-35

10.1097/01.mat.0001169056.09544.df Get It

77: Outcomes of Renal Replacement Therapy Use in Post-Cardiotomy ECMO
Wieruszewski, Patrick, Peffley, Nathan, Barreto, Erin, Seelhammer, Troy, Brinkman, Hannah, Wittwer, Erica, Wieruszewski, Patrick, Peffley, Nathan, Barreto, Erin, Seelhammer, Troy, Brinkman, Hannah, Wittwer, Erica

Mayo Clinic

ASAIO Journal | September 26, 2025 | Volume: 71 | Issue: Supplement 4 | Pages: 6-6

10.1097/01.mat.0001168832.26173.52 Get It

One Size Does Not Fit All: Evidence Synthesis Methods Must Be Adapted to the Systematic Review Question
Wieruszewski, Patrick M. , Brinkman, Hannah M. , Ursoleo, Jacopo D’Andria , Wieruszewski, Erin D. , Seelhammer, Troy G. , Wieruszewski, Patrick M , D'Andria Ursoleo, Jacopo , Ortoleva, Jamel P.

Mayo Clinic

ASAIO Journal | September 10, 2025 | Volume: 72 | Issue: 1 | Pages: e18-e18

10.1097/mat.0000000000002549 | PMID 40928094 Get It

Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
Wieruszewski, Patrick M. , Brinkman, Hannah M. , Ripoll, Juan G. , Pieterick, Sarah E., Damico, Katharine, Wittwer, Erica D. , Gerberi, Dana , Ursoleo, Jacopo D’Andria , Wieruszewski, Erin D. , Seelhammer, Troy G. , Normand, Sarah , Damico, Katharine E, Wieruszewski, Patrick M , D'Andria Ursoleo, Jacopo , Pieterick, Sarah E , Ortoleva, Jamel P. , Chatterjee, Subhasis

Mayo Clinic

ASAIO Journal | July 17, 2025 | Volume: 71 | Issue: 9 | Pages: 691-700

10.1097/mat.0000000000002512 | PMID 40673548 Get It

Empirical evidence suggests direct thrombin inhibitors (DTIs) produce more favorable hemostatic outcomes than heparin in patients supported by extracorporeal membrane oxygenation (ECMO), yet the exact mechanisms responsible are unknown. We systematically searched databases and registers for studies comparing DTIs to heparin in humans receiving ECMO. A total of 28 studies were identified, most of which (n = 25) used bivalirudin, while the rest (n = 3) used argatroban. In random-effects meta-analysis, DTIs achieved the therapeutic anticoagulation range faster (mean difference = −6.96 hours, 95% confidence interval [CI] = −11.98 to −1.95, p = 0.006) and maintained the therapeutic range for a greater proportion of time (mean difference = 18.6%, 95% CI = 8.78–28.42, p < 0.001) than heparin. Subgroup analysis revealed these effects were similarly significant in adult patients and when bivalirudin was the DTI; however, they were not significant in pediatric patients or when argatroban was the DTI. Sensitivity analysis confirmed robustness of the primary findings in only low-risk of bias studies and in only studies published as full papers. In summary, DTIs—specifically bivalirudin—were associated with faster time to therapeutic anticoagulation and maintained the goal range for a greater percentage of time than heparin during ECMO support.
1646: TIMING OF PEAK VASOPRESSOR EXPOSURE IN REFRACTORY SEPTIC SHOCK
Brinkman, Hannah M. , Thompson, Hailey, Cole, Kristin, Wittwer, Erica D. , Kashani, Kianoush , Cole, Kristin, Wieruszewski, Patrick M.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001105248.26221.d5 Get It

193: MIDODRINE TO FACILITATE VASOPRESSOR WEANING IN PATIENTS UNDERGOING CARDIOVASCULAR SURGERY
Warfield, Micaela , Brinkman, Hannah M. , Everson, Brianna, Hickox, Benjamin C., Jacobson, M., Wittwer, Erica D. , Wieruszewski, Patrick M.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001099436.73923.4e Get It